Advertorial

Lorenz Mayr joins Drug Discovery 2017 speaker lineup

Posted: 31 January 2017 | | No comments yet

Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.

With a focus on CRISPR/Cas9 technology, Lorenz’s keynote address will explore how this new emerging technique has become a pivotal new approach for drug discovery, particularly in target discovery, hit finding and translational studies. A few key points include:

  • an overview of PGE and introduction to CRISPR/Cas9 technology
  • applications in target finding, hit and lead discovery, efficacy and safety models
  • AstraZeneca’s unique approach towards innovation and collaboration
  • case studies from AstraZeneca’s drug discovery programme
  • future outlook of PGE for drug discovery and therapeutic applications.

Lorenz will be speaking on Day 1 of the conference and joins lead decision-makers and industry innovators from Sanofi, Takeda, Merck Serono, AbbVie, GSK, Johnson & Johnson, UCB Pharma, Eli Lilly and more. A full list of speakers can be found on www.drug-discovery.co.uk/DTR.

SMi’s Drug Discovery conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

 

access your free copy

 


Biomarkers are redefining how precision therapies are discovered, validated and delivered. 

This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today

 

The event will also feature two post-conference workshops on new approaches in lead generation and applications of physicochemical and biomimetic properties in early drug discovery.

For more details about the conference and to register, visit www.drug-discovery.co.uk/DTR.

Drug Discovery

27 – 28 March2017
Holiday Inn Kensington Forum
www.drug-discovery.co.uk/DTR

Related organisations
, , , ,

Related people

Leave a Reply

Your email address will not be published. Required fields are marked *